— Know what they know.
Not Investment Advice

SAGE NASDAQ

Sage Therapeutics, Inc.
1W: -0.9% 1M: -4.4% 3M: +19.1% 1Y: -19.7% 3Y: -74.8% 5Y: -81.6%
$8.68
Last traded 2025-07-31 — delisted
NASDAQ · Healthcare · Biotechnology · $544.9M mcap · 51M float · 4.83% daily turnover · Short 37% of daily vol

Supply Chain Overview

2 relationships
0
As Filer
counterparties named
2
As Counterparty
mentioned by others
2025-06-16
Earliest Filing
2025-07-31
Latest Filing

Mentioned As Counterparty

2 mentions

Other companies that named SAGE in their SEC 8-K filings.

Filed By Relationship Summary Filing Date SEC
SUPN SUPERNUS PHARMACEUTICALS, INC. acquirer Target company acquired in a merger agreement 2025-07-31 View
SUPN SUPERNUS PHARMACEUTICALS, INC. acquirer Target company in a merger agreement where Supernus Pharmaceuticals will acquire it via a tender offer. 2025-06-16 View
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text. Covers 2021–2026. View on SEC EDGAR

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms